Bart Vanmedegael is a passionate leader dedicated to transforming healthcare and improving patient outcomes. With more than 20 years of experience in the life sciences industry, Bart brings strategic expertise and a progressive approach to global marketing. As Global Strategic Marketing Lead MG at UCB, he oversees the global launch of portfolio assets in Myasthenia Gravis, life cycle management, and the evolution of go-to-market strategies. His expertise spans marketing strategy, business development, product launches, and value-based partnerships, with a proven track record of success across Europe and the United States. Previously, Bart held leadership roles at Amgen, Nutricia and Cegedim where he drove commercial strategy and led global launches for breakthrough therapies in bone health, cardio-renal, epilepsy, and rare diseases. Fluent in English, Dutch, French, and German, Bart is known for his analytical mindset, collaborative leadership, and energetic problem-solving—and remains deeply committed to advancing healthcare innovation on a global scale.